Table 4.

Effects of clinically established drugs and CXL-1020 when administered in combination on estimated mechanical energy and LV hemodynamics indices in instrumented anesthetized normal rats.

Parameters	Drug	Normal
		Baseline	Drug	% Δ from baseline
MAP (mmHg)	CXL-1020	123 ± 4	92 ± 9*	−26 ± 6
	CXL-1020 + ENA	–	69 ± 9	−44 ± 7#
	CXL-1020	114 ± 5	85 ± 5*	−26 ± 4
	CXL-1020 + MET	–	67 ± 5	−41 ± 5#
	CXL-1020 + DOB	–	81 ± 6	−29 ± 5
PVA (mmHg * RVU * 103)	CXL-1020	2.7 ± 0.5	1.9 ± 0.3*	−28 ± 6
	CXL-1020 + ENA	–	1.7 ± 0.3*	−33 ± 5
	CXL-1020	3.9 ± 0.6	2.5 ± 0.4*	−37 ± 7
	CXL-1020 + MET	–	2.4 ± 0.3*	−43 ± 6
	CXL-1020 + DOB	–	4.5 ± 0.7*	24 ± 16#
PRSW (mmHg)	CXL-1020	56 ± 11	79 ± 8	56 ± 10
	CXL-1020 + ENA	–	76 ± 5	56 ± 20
	CXL-1020	48 ± 5	73 ± 11	51 ± 15
	CXL-1020 + MET	–	64 ± 6	39 ± 19
	CXL-1020 + DOB	–	114 ± 9	125 ± 20#

Summary data as % change from baseline of CXL-1020 administered with an ACE inhibitor, (ENA, 1 mg/kg/h, n = 5), β-AR blocker, MET (1 mg/kg/h, n = 7), and β-AR 1 agonist, DOB (5 μg/kg/min, n = 7).

^*P < 0.05 vs. corresponding baseline,

^#P < 0.05 vs. corresponding CXL-1020 alone.